Relugolix - Sumitomo Pharma America/Takeda
Alternative Names: MVT-601 - Sumitomo Pharma America/Takeda; ORGOVYX; Relumina; RVT 601; T-1331285; TAK-385Latest Information Update: 20 Aug 2024
At a glance
- Originator Takeda
- Developer ASKA Pharmaceutical; Sumitomo Pharma America; Takeda; Takeda Oncology
- Class Analgesics; Antineoplastics; Fluorobenzenes; Ketones; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
- Mechanism of Action LHRH receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Registered Endometriosis; Uterine leiomyoma
- Phase II Pain
- No development reported Solid tumours
Most Recent Events
- 14 Aug 2024 The UK's NICE recommends Relugolix (ORGOVYX®) as the first oral ADT treatment for hormone sensitive prostate cancer in England
- 12 Mar 2024 Launched for Prostate cancer (Late-stage disease, Metastatic disease) in Canada (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)